Toggle Main Menu Toggle Search

Open Access padlockePrints

Ataluren treatment of patients with nonsense mutation dystrophinopathy

Lookup NU author(s): Emerita Professor Katherine Bushby, Dr Michelle Eagle

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).


Abstract

Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males >= 5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Delta=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.


Publication metadata

Author(s): Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Sweeney HL, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'Donnell MW, Peltz SW, McDonald CM, PTC124-GD-007-DMD Study Grp

Publication type: Article

Publication status: Published

Journal: Muscle & Nerve

Year: 2014

Volume: 50

Issue: 4

Pages: 477-487

Print publication date: 01/10/2014

Online publication date: 22/09/2014

Acceptance date: 01/07/2014

Date deposited: 09/09/2015

ISSN (print): 0148-639X

ISSN (electronic): 1097-4598

Publisher: Wiley-Blackwell Publishing Ltd.

URL: http://dx.doi.org/10.1002/mus.24332

DOI: 10.1002/mus.24332

PubMed id: 25042182


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
MR/K000608/1Medical Research Council
T32 NS007338NINDS NIH HHS
U54 NS053672NINDS NIH HHS
UL1 RR024134NCRR NIH HHS
UL1-RR-024134NCRR NIH HHS

Share